A detailed history of Brave Asset Management Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Brave Asset Management Inc holds 2,740 shares of ABBV stock, worth $496,323. This represents 0.13% of its overall portfolio holdings.

Number of Shares
2,740
Previous 2,740 -0.0%
Holding current value
$496,323
Previous $469,000 15.35%
% of portfolio
0.13%
Previous 0.12%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 15, 2024

BUY
$154.79 - $180.76 $41,483 - $48,443
268 Added 10.84%
2,740 $469,000
Q1 2024

Apr 29, 2024

SELL
$159.82 - $182.1 $14,703 - $16,753
-92 Reduced 3.59%
2,472 $450,000
Q4 2023

Jan 18, 2024

BUY
$137.6 - $154.97 $16,924 - $19,061
123 Added 5.04%
2,564 $397,000
Q3 2023

Oct 13, 2023

SELL
$133.59 - $154.65 $23,378 - $27,063
-175 Reduced 6.69%
2,441 $363,000
Q1 2023

Apr 12, 2023

BUY
$144.61 - $166.54 $14,461 - $16,654
100 Added 3.97%
2,616 $416,000
Q1 2022

Apr 22, 2022

SELL
$131.98 - $163.75 $3,167 - $3,930
-24 Reduced 0.94%
2,516 $408,000
Q4 2021

Jan 21, 2022

SELL
$107.43 - $135.93 $2,578 - $3,262
-24 Reduced 0.94%
2,540 $344,000
Q3 2021

Nov 02, 2021

BUY
$106.4 - $120.78 $5,107 - $5,797
48 Added 1.91%
2,564 $277,000
Q1 2021

Apr 26, 2021

BUY
$102.3 - $112.62 $257,386 - $283,351
2,516 New
2,516 $272,000
Q4 2020

Jan 27, 2021

SELL
$80.49 - $108.67 $202,512 - $273,413
-2,516 Closed
0 $0
Q2 2020

Jul 23, 2020

BUY
$73.37 - $98.18 $184,598 - $247,020
2,516 New
2,516 $247,000
Q1 2019

May 03, 2019

SELL
$77.14 - $90.79 $169,708 - $199,738
-2,200 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$89.56 - $98.21 $197,032 - $216,062
2,200
2,200 $213,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $320B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Brave Asset Management Inc Portfolio

Follow Brave Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brave Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Brave Asset Management Inc with notifications on news.